Oura agreed on November 10 to acquire Counsel Health, an AI-native primary care startup, for $625 million1,9,3. The deal arrived weeks after Oura shelved a planned IPO, citing "uncertainty in the IPO market". Rather than wait for public-market conditions to improve, Oura is spending its way into a different business: one where the smart ring is not the product but the front door to a clinical AI service that can diagnose, prescribe, and refer.
ANALYSIS That is the argument worth testing. Oura is wagering that the highest-value position in consumer health AI is not the data layer (rings, watches, patches) and not the cloud orchestration layer (where Google just placed its own bet with Gemini for Healthcare), but the integrated vertical: sensor plus clinical AI plus physician, all inside a single app. The $625 million price tag — roughly 17× total funding of $36 million — says Oura's leadership believes this vertical is worth paying up for now rather than building later11.
The financial context makes the bet legible. Oura reported Q4 revenue of $533 million, up 153% year over year, and full fiscal-year 2026 revenue of $1.75 billion, up 92%. Those are hardware-company growth rates that fund an acquisition of this size without dilutive public equity. "Oura helps members understand their physiology and, with Counsel, they can take action on their health across a range of needs, from quick questions and prescriptions to lab results, chronic care, and referrals," said CEO Tom Hale. The language is deliberate: "take action" is the gap between a sleep score and a clinic visit, and Counsel is meant to close it.
Counsel Health's service was integrated into the Oura app in June. Users can chat with Counsel's medical AI for personalized advice and connect with a licensed physician when needed. Counsel CEO Muthu Alagappan will become Oura's chief clinical AI officer, and roughly 70 Counsel employees are joining. The companies plan to expand across preventative care, acute care, and specialty and chronic care. Oura expects the deal to close before year-end.
The acquisition multiple deserves scrutiny. Counsel Health raised a $25 million Series A roughly a year ago, led by Andreessen Horowitz and GV, with PitchBook estimating total funding at about $36 million. A $625 million exit on $36 million raised represents a substantial return for those investors, but for Oura, the price reflects the strategic premium of owning the clinical layer outright rather than licensing it. Counsel is small (about 70 people), so Oura is paying for the regulatory scaffolding and the physician network, not headcount. Whether Counsel's clinical AI models were specifically trained on wearable-derived biometric data, as opposed to generic medical corpora, is unconfirmed in public disclosures. If the models are wearable-native, the premium is easier to justify; if they are not, Oura is paying $625 million largely for a licensure framework and a small physician panel, assets that are replicable.
The competitive pressure is real. Rivals RingConn and Ultrahuman are challenging Oura's dominance in the smart ring market. A ring that only tracks biometrics is increasingly commoditized; a ring that connects to a doctor is a different product category, and Oura is trying to define it before its hardware competitors do.
The same day Oura announced the Counsel deal, Google Cloud put forward a structurally different answer to the same question: how AI enters clinical workflows. Google launched Gemini for Healthcare in U.S. preview, an enterprise agentic orchestration layer for health systems, medical groups, and health plans4. Where Oura is going vertical (sensor to doctor, one app, one company), Google is going horizontal. Gemini for Healthcare connects to existing electronic health records like Epic and Oracle Health through what Google calls "connectors," with more than 24 launch partners including UiPath, InterSystems, Workday, and ServiceNow2,6,7.
Aashima Gupta, Google Cloud's global leader of healthcare, framed the problem as administrative friction: "Most of the systems do not talk to each other, not to mention the PDFs, the clipboards that we walk walk with". Google's platform addresses this with modular "skills" that teach the Gemini agent to execute multi-step healthcare workflows under role-based access control. UiPath's Model Context Protocol Server, available in preview through Gemini for Healthcare, lets organizations connect Gemini to automations already governed on the UiPath platform8. InterSystems' IRIS FHIR MCP server provides standards-based access to health data. "We are establishing a trusted bridge between advanced AI and the health information these organizations rely on," said Don Woodlock, president of InterSystems.
The two models are not directly competitive today, and the asymmetry is vast: Google's platform targets the institutional infrastructure through which the majority of U.S. healthcare spending flows; Oura targets consumers who may or may not want clinical services from a ring company. But both are attacking the same structural bottleneck, the gap between health data and clinical action, from opposite ends. Oura's approach collapses the stack into a single consumer product. Google's approach federates it across dozens of enterprise partners. The consumer model is faster to deploy (one app update) but narrower in clinical scope and unproven at scale; Counsel's roughly 70-person team has disclosed no utilization metrics since its June integration, and it is unclear whether physician availability can match Oura's user base without degrading response times. The enterprise model is slower (24-plus integrations to coordinate) but maps onto the institutional infrastructure where most healthcare spending actually occurs. Framing these as symmetric alternatives overstates Oura's current position; the comparison is useful for understanding architectural choices, not competitive parity.
By acquiring Counsel, Oura can return to public markets with a different story: not a hardware company selling rings, but a health platform generating recurring clinical revenue. Whether that narrative actually improves the IPO prospect is an open question. Public-market investors may see a $625 million acquisition of a roughly 70-person startup with no disclosed revenue as a distraction from core hardware margins rather than a platform upgrade. The bet is that owning a doctor service changes the multiple; the risk is that it merely changes the cost structure.
Google's Gemini for Healthcare advances a pattern Vector Wire identified in August: the enterprise AI market splitting into agents that do work and control planes that govern them. Google is positioning Gemini as the orchestration layer, with partners like UiPath and InterSystems providing the execution and data layers. Providers currently spend nearly 28 hours per week manually reconciling clinical information across disconnected systems, according to Google Cloud. That administrative burden is the addressable market for the orchestration model. Health systems must adopt yet another platform, the perennial friction in enterprise healthcare IT, and Google must price the orchestration layer sustainably while its own AI infrastructure costs remain elevated.
What to watch. Whether Oura's Counsel integration produces measurable clinical utilization metrics (consultations per ring user, prescriptions written) before a renewed IPO filing. Whether Google names anchor health-system customers for Gemini for Healthcare beyond the preview phase; the 24-plus partner count is a supply-side number, and demand-side adoption is what matters. Whether Counsel's roughly 70-person team can scale physician availability to match Oura's user base without degrading response times, the constraint that separates an AI chatbot from a functioning clinic and the one most likely to determine whether the $625 million was a platform investment or an expensive acqui-hire. The deal is expected to close before year-end, and Google's platform is in U.S. preview now.